by Kristi K. Snyder, Robert G. Van Buskirk, PhD, Aby J. Mathew, PhD, John G. Baust, PhD, and John M. Baust, PhD
Volume 3, Issue 3 (May/June 2004)
The globalization and sustained growth of the biotechnology market has brought the issue of biological packaging to the fore, particularly for those companies invested in cell and tissue bioproducts, such as engineered tissues and cells used for cell therapy. Biological packaging can be defined as the sum total of the physical device, temperature regulating and monitoring systems, type of preservation solution, and storage protocol(s) necessary to maintain cells or tissues in a “state of suspended animation” during transport or storage. The ideal biological package provides for the transport of cells and tissues throughout the global marketplace while maintaining both the viability and the function of the biological system at levels equivalent to those measured prior to shipment. Cells and tissues are currently shipped and stored under hypothermic (4–8ºC) or cryopreserved (–80 to –196ºC) conditions. These two processes have remained relatively unchanged over the past several decades, limiting their utility in the storage of modern bioproducts. However, recent evolutions in biological packaging have begun to provide scientific and financial benefits to researchers, clinicians, and corporate entities…
Citation:
Snyder KK, Van Buskirk RG, Mathew AJ, Baust JG, Baust JM. Biological Packaging for the Global Cell and Tissue Therapy Markets. BioProcess J, 2004; 3(3): 39-45.